Biosimilar Development solution center

1. Effectively Educating Clinicians And Patients On Biosimilars Across Europe: Getting The Right Message Across 3/31/2021

   Biosimilars are here to stay, so it is essential that the different stakeholder groups (healthcare providers, patients) receive trustworthy and clear information about the principles and the value proposition.

2. Assessing CT-P13 SC’s Impact Across Indications 3/24/2021

   This is the second article in a two-part series exploring the anticipated competitive dynamics for Celltrion’s subcutaneous (SC) infliximab bio-better, CT-P13 SC, in the U.S.The author explores how market dynamics across different autoimmune indications will drive distinct uptake of CT-P13 SC, highlighting the potential impact on TNF inhibitor competition.

3. Subcutaneous Infliximab In The U.S.: Defining CT-P13 SC’s Competitive Edge 3/17/2021

   TNF inhibiting biologics still reign supreme when treating immunological diseases. GlobalData believes that Celltrion’s CT-P13 SC will likely see better success than IV infliximab biosimilars in the U.S. In Part 1 of this two-part article series, we assess the factors that may give CT-P13 SC a competitive edge over Remicade and IV infliximab biosimilars.

4. The Biosimilar Leadership Playbook: 5 Tips For Success 2/10/2021

   In the next five to 10 years, what will define a leader in the biosimilar space? Which skills will be the most important to long-term growth in the biosimilar space? Here McKinsey & Co.'s Jorge Santos da Silva shares five specific best practices emerging for any company looking to be — or remain — a leader in the biosimilar space. 

5. The Opportunities & Challenges Of India’s Biologics Market 1/27/2021

   Biosimilar drugs, due to their affordability, can play an important role and allow the Indian government to have a better healthcare system. However, as issues remain on the regulatory and manufacturing sides, India needs to see strong improvements to compete and appear as an important hub nationally and internationally.

6. Will It Be Biologics Business As Usual In 2021, Or Will Biosimilars Mean Business? 1/20/2021

   In this fourth installment of the Editorial Board 2021 Outlook, it's clear that stakeholders are relying more heavily on biosimilars and that it’s more important than ever for biosimilar companies to keep carrying the torch for more competition, cost-savings, value, and responsible pricing.

7. The Top 5 Biosimilar Developments Of 2020 12/30/2020

   Though 2020 felt like an endless descent into Dante’s Nine Circles of Hell, I wanted to end the year as I typically do: with a column highlighting the most important and positive biosimilar developments from the past 12 months.

8. The Second Wave Of Biosimilars: New Scenarios, New Rules 12/15/2020

   The arrival of what we could call the first “bio patent cliff” has revealed important lessons that should be taken into consideration when selecting new candidates for the second and third waves.

9. Biosimilar Experts Reflect On 2020’s Greatest Biosimilar Achievements 12/9/2020

   As the amazing members of the Biosimilar Development Editorial Board emphasize here, there is a lot to be thankful for in the biosimilar world. Check out the first of what will be a four-part series showcasing the editorial board’s thoughts on the past year and the year(s) ahead.

10. Accelerate Your Pipeline With CDMO Collaboration 12/1/2020

    Collaborating with a CDMO can augment your capacity and expertise, refine your processes, and ultimately shorten your time to market. This ebook offers best practices that make working with a CDMO as efficient as possible.